Pricey weight loss drugs like Wegovy and Mounjaro have exploded in popularity, creating opportunities for counterfeit drug manufacturers and challenges for regulators and enforcers. In the final episode of Season 5, Keturah Taylor talks with Cozen O’Connor colleagues Danielle Sapega and Rick Van Buren about the state of federal and state regulation and enforcement and they outline a road map to help legitimate market participants avoid pitfalls.

Read More

New Mexico AG Raúl Torrez announced settlements with Sanofi-Aventis U.S. LLC and Novo Nordisk Inc. to resolve allegations that the pharmaceutical companies’ pricing policies resulted in underinsured and uninsured patients paying higher prices for insulin. Under the terms of the agreements, Sanofi-Aventis and Novo Nordisk will cap the price of insulin at $35 per month for…

Read More

Connecticut AG William Tong announced enforcement actions against companies that allegedly advertised, distributed, or sold so-called “research grade” versions of GLP-1 weight loss drugs in violation of state consumer protection laws. The AG sued Triggered Brand for allegedly marketing and selling “research grade” versions of GLP-1 drugs that do not have FDA approval for human…

Read More

Maine AG Aaron Frey announced a settlement with Sanofi-Aventis U.S. LLC to resolve allegations that the pharmaceutical company’s deceptive pricing policies resulted in underinsured and uninsured patients having to pay higher list prices for insulin. According to the AG’s office, Sanofi will cap out-of-pocket insulin costs at $35 per month for Maine consumers through 2029. …

Read More

A bipartisan coalition of 50 AGs settled with Walgreens Boots Alliance, Inc. and Walgreen Co. (collectively, “Walgreens”) to resolve allegations that they billed federal and state government health care programs for prescriptions that were never picked up, in violation of the federal False Claims Act. According to the settlement agreement, Walgreens allegedly billed Medicare, Medicaid, and…

Read More